EUIPOProtect this trademark from copycats!
With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.
The Union trademark WAR-LOCK was filed as Word mark on 06/12/2023 at the European Union Intellectual Property Office.
It was registered as a trademark on 10/17/2023.
The current status of the mark is "Trademark registered".
| Trademark form | Word mark |
| File reference | 018886865 |
| Application date | June 12, 2023 |
| Publication date | July 10, 2023 |
| Entry date | October 17, 2023 |
| Expiration date | June 12, 2033 |
Trademark owner
11099 North Torrey Pines Road, Suite 280
92037 La Jolla
US
92037 La Jolla
US
Trademark representatives
Leopoldstr. 4
80802 München
DE
goods and services
1
Chemical products for use in industry and science; reagents for use in scientific apparatus for chemical or biological analysis; reagents for medical research; antibody reagents for scientific purposes; in-vivo diagnostic reagents for scientific or research use; enzymes for scientific use; cell culture media for use in scientific research; active chemical ingredients for use in the manufacture of anti-cancer drugs; laboratory chemicals, namely, an antibody reagent used for the detection of cancerous tumors; antibodies for research use
5
Pharmaceutical products, preparations, and substances for the treatment of cancer; cancer therapeutics, namely, anti-cancer preparations; novel cancer therapies, namely, pharmaceutical preparations and substances for the treatment of cancer and tumors; biological preparations and substances for the treatment, diagnosis, detection, and prevention of cancer; pharmaceutical products consisting of covalent protein biologics; pharmaceutical products, namely, covalent protein drugs; pharmaceuticals products consisting of synthetic biology enabled covalent protein biologics; pharmaceutical products consisting of covalent protein drugs; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals
42
Research and development in the field of covalent protein biologics; medical and scientific research in the field of cancer treatment and diagnosis; pharmaceutical research and development; research and development of pharmaceuticals and biologicals in the field of cancer therapeutics; research and development in the field of synthetic biology enabled covalent therapeutics and covalent protein drugs; research and development for the purpose of selective covalent modification of proteins; research and development in the field of oncology, namely, development of a biotechnology platform to create covalent protein biologics for treating cancer; research and development in the field of covalent protein drugs, namely, development of a platform technology for identification of small-molecule and biologic therapeutics for treating cancer and targeting tumors; conducting clinical trials for others in the field of cancer therapeutics; biotechnology testing services, namely, synthetic chemistry, recombinant protein production, bioconjugation, testing, and analysis; research and development services in the field of antibody-drug conjugates, T cells, natural killer (NK) cells, and macrophage engaging antibodies; research and development services for the purpose of antibody engineering, namely, custom design and engineering of antibodies
ID: 11018886865